the effect of rivaroxaban on the prevention of deep vein thrombosis in nephrotic syndrom
Phase 3
Recruiting
- Conditions
- ephrotic syndrom.Nephrotic syndrome
- Registration Number
- IRCT20220422054617N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Newly diagnosed nephrotic syndrome
Albumin less than 2.5 in a patient with MGN
Albumin less than 2 in other cases of nephrotic syndrome
The age of the patient is between 18 and 60 years
The patient's bleeding risk according to HAS-BLED criteria is low to moderate risk
GFR greater than 60
Exclusion Criteria
coagulation disorders
pregnancy
active cancer
taking aspirin
taking plavix
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Deep vein thrombosis after taking rivaroxaban. Timepoint: At the beginning of the study and once every three months. Method of measurement: Color Doppler ultrasound of the deep veins of the lower extremities and renal arteries.
- Secondary Outcome Measures
Name Time Method